HER2CLIMB, DESTINY-Breast01, and SOPHIA trials: Benefits of combination therapies for HER2+ breast cancers
Key Takeaways
Matteo Lambertini, MD, PhD, San Martino Hospital, Genoa, Italy, reviewed some of the highlights presented at SABCS 2019. In the advanced HER2-positive breast cancer setting, researchers of the HER2CLIMB trial found significant benefits to adding tucatinib to trastuzumab and capecitabine treatment in pretreated patients with HER2-positive advanced disease. Of particular importance were the significant benefits for patients with brain metastases.
Researchers of the DESTINY-Breast01 phase 2 trial demonstrated that treatment with trastuzumab deruxtecan—an antibody-drug conjugate—effected a clinically meaningful and durable response in heavily pretreated patients with HER2-positive metastatic breast cancer, with a generally manageable safety profile. In the SOPHIA trial, margetuximab plus chemotherapy improved progression free survival compared with trastuzumab, with comparable safety results in women with pretreated HER2-positive metastatic breast cancer.
These results were shared at SABCS 2019.
ecancer aims to raise the standards of care for cancer patients across the world through education. Visit ecancer.org to find how we can support your education through our high-quality and free resources.
